BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Accenture
McKinsey
McKesson
Colorcon
Baxter
AstraZeneca
Citi
Healthtrust
Cantor Fitzgerald

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,704,947

« Back to Dashboard

Which drugs does patent 7,704,947 protect, and when does it expire?

Patent 7,704,947 protects LINZESS and is included in one NDA.

This patent has seventy-four patent family members in twenty-four countries.
Summary for Patent: 7,704,947
Title:Methods and compositions for the treatment of gastrointestinal disorders
Abstract: The present invention features compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), Crohn's disease, ulcerative colitis, Inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.
Inventor(s): Currie; Mark G. (Sterling, MA), Mahajan-Miklos; Shalina (Stanford, CA), Norman; Thea (San Diego, CA), Milne; G. Todd (Brookline, MA)
Assignee: Ironwood Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:11/930,696
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 7,704,947

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Forest Labs Llc LINZESS linaclotide CAPSULE;ORAL 202811-003 Jan 25, 2017 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Forest Labs Llc LINZESS linaclotide CAPSULE;ORAL 202811-001 Aug 30, 2012 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Forest Labs Llc LINZESS linaclotide CAPSULE;ORAL 202811-002 Aug 30, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,704,947

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,910,546 Methods and compositions for the treatment of gastrointestinal disorders ➤ Subscribe
7,304,036 Methods and compositions for the treatment of gastrointestinal disorders ➤ Subscribe
7,371,727 Methods and compositions for the treatment of gastrointestinal disorders ➤ Subscribe
8,080,526 Methods and compositions for the treatment of gastrointestinal disorders ➤ Subscribe
7,772,188 Methods and compositions for the treatment of gastrointestinal disorders ➤ Subscribe
7,745,409 Methods and compositions for the treatment of gastrointestinal disorders ➤ Subscribe
8,110,553 Methods and compositions for the treatment of gastrointestinal disorders ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,704,947

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 365174 ➤ Subscribe
Austria 477268 ➤ Subscribe
Australia 2004210161 ➤ Subscribe
Australia 2005222387 ➤ Subscribe
Australia 2009235993 ➤ Subscribe
Brazil PI0407071 ➤ Subscribe
Brazil PI0508558 ➤ Subscribe
Canada 2514507 ➤ Subscribe
Canada 2558050 ➤ Subscribe
China 100589839 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Citi
Covington
AstraZeneca
McKesson
Teva
Dow
Daiichi Sankyo
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot